



(±) -10-Hydroxycamptothecin

Catalog No: tcsc0008775

| Available Sizes | |
|---|--|
| Size: 25mg | |
| Size: 50mg | |
| Size: 100mg | |
| Specifications | |
| CAS No: 64439-81-2 | |
| Formula: $C_{20}^{H}_{16}^{N}_{2}^{O}_{5}$ | |
| Pathway: Cell Cycle/DNA Damage | |
| Target: Topoisomerase | |
| Purity / Grade: >98% | |
| Solubility: DMSO: ≥ 37.5 mg/mL | |
| Observed Molecular Weight: 364.35 | |

Product Description

(±)-10-Hydroxycamptothecin, an indole alkaloid isolated from Camptotheca acuminate, inhibits the activity of **topoisomerase I** and has a broad spectrum of anticancer activity.



IC50 & Target: Topoisomerase I^[1]

In Vitro: (\pm)-10-Hydroxycamptothecin (10-OH-camptothecin) is an inhibitor of topo I^[1]. (\pm)-10-Hydroxycamptothecin (10-HCPT, 5-20 nM) markedly inhibits the proliferation of Colo 205 cells in a dose-dependent manner. (\pm)-10-Hydroxycamptothecin (5-20 nM) arrests Colo 205 cells in the G2 phase of the cell cycle and triggers apoptosis through a caspase-3-dependent pathway^[2]. (\pm)-10-Hydroxycamptothecin (HPT, 0.01-10 µg/mL) causes cell shrinage, nuclear fragmentation and condensed chromosomes and induces apoptosis of human urinary bladder cancer cell line (T24)^[3].

In Vivo: (\pm) -10-Hydroxycamptothecin (10-HCPT, 2.5-7.5 mg/kg/2 days, p.o.) significantly suppresss tumor growth in mouse xenografts. (\pm) -10-Hydroxycamptothecin (1-7.5 mg/kg, p.o., once per 2 or 4 days) causes no obvious acute toxicity in nude mice^[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!